IMM Insider Trading

Insider Ownership Percentage: 3.81%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Immutep Insider Trading History Chart

This chart shows the insider buying and selling history at Immutep by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immutep Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IMM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Immutep Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2023Lis (Elisabeth) BoyceInsiderIssued589,955A$0.30A$174,036.73
10/3/2023Pete MeyersInsiderIssued500,000A$0.29A$142,500.00
12/21/2022Russell HowardInsiderExercise113,207A$0.29A$32,830.03
10/3/2022Frederic TriebelInsiderExercise900,000A$0.24A$216,000.00
12/1/2021Russell HowardInsiderExercise250,000A$0.48A$118,750.00
10/4/2021Pete MeyersInsiderExercise500,000A$0.54A$267,500.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Immutep (ASX:IMM)

38.38% of Immutep stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Immutep logo
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.
Read More on Immutep

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


2,151,332 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Immutep?

Immutep's top insider investors include:
  1. Frederic Triebel (Insider)
  2. Lis (Elisabeth) Boyce (Insider)
  3. Pete Meyers (Insider)
  4. Russell Howard (Insider)
Learn More about top insider investors at Immutep.